IFN-λ4 is a novel type-III interferon with strong clinical significance in humans. Only a subset of individuals—up to 10% of Asians, 50% of Europeans, and 90% of Africans—carry the ΔG allele of a genetic variant rs368234815-TT/ΔG and are genetically able to produce IFN-λ4 protein. Carriers of the ΔG allele have impaired ability to clear infection with hepatitis C virus (HCV). IFN-λ4 is also predicted to exist and be functionally important in several nonhuman mammals. In this study, we present the first comparative analysis of 12 mammalian IFN-λ4 orthologs in a human hepatic cell line, HepG2, which supports signaling of the human IFN-λ4. We show that despite differences in protein sequences, functional properties of the recombinant human and nonhuman IFN-λ4 proteins are comparable—they are all expressed as predominantly cytoplasmic proteins that are biologically active for induction of interferon signaling. We show that several IFN-λ4 orthologs can be detected by Western blotting, flow cytometry, and confocal imaging using a monoclonal antibody developed for the human IFN-λ4. Studies of IFN-λ4 in animals should help improve our understanding of the biology of this novel clinically important interferon in normal and disease conditions.
Get full access to this article
View all access options for this article.
References
1.
AkaPV, KuniholmMH, PfeifferRM, WangAS, TangW, ChenS, AstemborskiJ, PlankeyM, VillacresMC, PetersMG, DesaiS, SeabergEC, EdlinBR, StricklerHD, ThomasDL, Prokunina-OlssonL, SharpGB, O'BrienTR. 2014. Association of the IFNL4-DeltaG Allele with impaired spontaneous clearance of Hepatitis C Virus. J Infect Dis, 209(3):350–354.
2.
BibertS, WojtowiczA, TaffeP, ManuelO, BernasconiE, FurrerH, GunthardHF, HoffmannM, KaiserL, OsthoffM, CavassiniM, BochudPY, SwissHIVCS. 2014. The IFNL3/4 DeltaG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. AIDS, 28(13):1885–1889.
3.
FrolichK, ThiedeS, KozikowskiT, JakobW. 2002. A review of mutual transmission of important infectious diseases between livestock and wildlife in Europe. Ann N Y Acad Sci, 969:4–13.
4.
GerdtsV, WilsonHL, MeurensF, van Drunen Littel-van den HurkS, WilsonD, WalkerS, WhelerC, TownsendH, PotterAA. 2015. Large animal models for vaccine development and testing. ILAR J, 56(1):53–62.
5.
HammingOJ, Terczynska-DylaE, VieyresG, DijkmanR, JorgensenSE, AkhtarH, SiupkaP, PietschmannT, ThielV, HartmannR. 2013. Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J, 32(23):3055–3065.
6.
JansDA, HassanG. 1998. Nuclear targeting by growth factors, cytokines, and their receptors: a role in signaling?. Bioessays, 20(5):400–411.
7.
JonesKE, PatelNG, LevyMA, StoreygardA, BalkD, GittlemanJL, DaszakP. 2008. Global trends in emerging infectious diseases. Nature, 451(7181):990–993.
8.
KeyFM, PeterB, DennisMY, Huerta-SanchezE, TangW, Prokunina-OlssonL, NielsenR, AndresAM. 2014. Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). PLoS Genet, 10(10):e1004681.
9.
KotenkoSV, GallagherG, BaurinVV, Lewis-AntesA, ShenM, ShahNK, LangerJA, SheikhF, DickensheetsH, DonnellyRP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol, 4(1):69–77.
10.
KumarKP, McBrideKM, WeaverBK, DingwallC, ReichNC. 2000. Regulated nuclear-cytoplasmic localization of interferon regulatory factor 3, a subunit of double-stranded RNA-activated factor 1. Mol Cell Biol, 20(11):4159–4168.
11.
LevyDE, MarieIJ, DurbinJE. 2011. Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol, 1(6):476–486.
12.
LuYF, GoldsteinDB, UrbanTJ, BradrickSS. 2015. Interferon-lambda4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden. Virology, 476:334–340.
13.
MachmachK, Abad-MolinaC, Romero-SanchezMC, Dominguez-MolinaB, MoyanoM, RodriguezMM, Rafii-El-Idrissi BenhniaM, Jimenez-MejiasME, VidalF, Munoz-FernandezMA, GenebatM, VicianaP, Gonzalez-EscribanoMF, LealM, Ruiz-MateosE. 2015. IFNL4 ss469415590 polymorphism is associated with unfavourable clinical and immunological status in HIV-infected individuals. Clin Microbiol Infect, 21(3):289e1–e4.
14.
ManuelO, WojtowiczA, BibertS, MuellerNJ, van DeldenC, HirschHH, SteigerJ, SternM, EgliA, GarzoniC, BinetI, WeisserM, BergerC, CusiniA, MeylanP, PascualM, BochudPY, Swiss Transplant CohortS, Swiss Transplant Cohort StudyS. 2015. Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. J Infect Dis, 211(6):906–914.
15.
MeurensF, SummerfieldA, NauwynckH, SaifL, GerdtsV. 2012. The pig: a model for human infectious diseases. Trends Microbiol, 20(1):50–57.
16.
NakaiK, HortonP. 1999. PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends Biochem Sci, 24(1):34–36.
17.
O'BrienTR, Prokunina-OlssonL, DonnellyRP. 2014. IFN-lambda4: the paradoxical new member of the interferon lambda family. J Interferon Cytokine Res, 34(11):829–838.
18.
OnabajoOO, Porter-GillP, PaquinA, RaoN, LiuL, TangW, BrandN, Prokunina-OlssonL. 2015. Expression of interferon lambda 4 is associated with reduced proliferation and increased cell death in human hepatic cells. J Interferon Cytokine Res doi: 10.1089/jir.2014.0161
19.
ParkinJ, CohenB. 2001. An overview of the immune system. Lancet, 357(9270):1777–1789.
20.
PetersenTN, BrunakS, von HeijneG, NielsenH. 2011. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat Methods, 8(10):785–786.
21.
Prokunina-OlssonL, MuchmoreB, TangW, PfeifferRM, ParkH, DickensheetsH, HergottD, Porter-GillP, MumyA, KohaarI, ChenS, BrandN, TarwayM, LiuL, SheikhF, AstemborskiJ, BonkovskyHL, EdlinBR, HowellCD, MorganTR, ThomasDL, RehermannB, DonnellyRP, O'BrienTR. 2013. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet, 45(2):164–171.
22.
RealLM, HerreroR, Rivero-JuarezA, CamachoA, MaciasJ, VicS, ViedmaS, SorianoV, GuardiolaJ, FiblaJ, RiveroA, PinedaJA, CaruzA. 2015. IFN-l4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection. AIDS, 29. doi: 10.1097/qad.0000000000000773
23.
SheppardP, KindsvogelW, XuW, HendersonK, SchlutsmeyerS, WhitmoreTE, KuestnerR, GarriguesU, BirksC, RorabackJ, OstranderC, DongD, ShinJ, PresnellS, FoxB, HaldemanB, CooperE, TaftD, GilbertT, GrantFJ, TackettM, KrivanW, McKnightG, CleggC, FosterD, KlucherKM. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol, 4(1):63–68.
24.
SubramaniamPS, MujtabaMG, PaddyMR, JohnsonHM. 1999. The carboxyl terminus of interferon-gamma contains a functional polybasic nuclear localization sequence. J Biol Chem, 274(1):403–407.
25.
ThumbiSM, NjengaMK, MarshTL, NohS, OtiangE, MunyuaP, OchiengL, OgolaE, YoderJ, AudiA, MontgomeryJM, BigogoG, BreimanRF, PalmerGH, McElwainTF. 2015. Linking human health and livestock health: a “one-health” platform for integrated analysis of human health, livestock health, and economic welfare in livestock dependent communities. PLoS One, 10(3):e0120761.
